Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
4103547 | American Journal of Otolaryngology | 2015 | 9 Pages |
Abstract
Routine HN-MRI for locoregional surveillance of OCSCC, when used in patients without concurrent suspicious symptoms or exam findings over 6Â months since treatment, may be unnecessary and costly given the very low rate of recurrence and high false positive rate. Our study supports the National Comprehensive Cancer Network guideline of limiting imaging after 6Â months of primary treatment completion to patients with suspicious clinical findings. Nonetheless, managing physicians should continue to be empowered to use surveillance imaging based on risk profiles and unique circumstances for each patient.
Related Topics
Health Sciences
Medicine and Dentistry
Otorhinolaryngology and Facial Plastic Surgery
Authors
Fatemah A. MD, Steven J. MD, Alina DO, Sue S. MD, PhD, William R. MD,